Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102635 · ClinicalTrials.gov registry record · Phase 1
4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00102635: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00102635 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00102635, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary objective of this study is to estimate the modulation of intermediate biological endpoints of the combination of 4-HPR and SCH66336, a farnesyl transferase inhibitor (FTI), across 4 randomly assigned dose levels in patients with locally advanced or recurrent head and neck cancer. We will also assess the activity, safety, tolerability and side effects of 4-HPR/SCH66336 and hope to establish a phase II regimen.
Interventions
- DRUG SCH66336
- DRUG Fenretinide (4-HPR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2005-01-20 |
| Est. Completion | 2006-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102635
The ClinicalTrials.gov registry entry for NCT00102635 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SCH66336 is the first listed.
NCT00102635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00102635 about?
NCT00102635 is a clinical study titled "4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)". The primary objective of this study is to estimate the modulation of intermediate biological endpoints of the combination of 4-HPR and SCH66336, a farnesyl transferase inhibitor (FTI), across 4 randomly assigned dose levels in patients with locally advanced or recurrent head and neck cancer. We will...
What is the current status of trial NCT00102635?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2005-01-20. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00102635?
The interventions under investigation include: SCH66336 (DRUG), Fenretinide (4-HPR) (DRUG).
Who is sponsoring clinical trial NCT00102635?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.